The Supreme Court Knocks Down Major Death Penalty Challenge

The court allows states to continue using the controversial execution drug midazolam.

Pat Sullivan/AP

Fight disinformation: Sign up for the free Mother Jones Daily newsletter and follow the news that matters.


On Monday, the Supreme Court rejected a challenge to a state lethal injection protocol, allowing Oklahoma and other states to continue using a controversial sedative that has been implicated in a number of botched executions. The 5-4 decision in Glossip v. Gross was a win for conservatives who support the death penalty and viewed the case’s technical dispute over one state’s lethal injection methods as part of a “guerilla war,” as Justice Samuel Alito put it during oral arguments, waged by opponents of capital punishment to end the death penalty. Alito wrote the opinion for the majority.

The case turned on the use of one particular drug that Oklahoma uses in executions. But it had far broader implications for the death penalty. In recent years, states have struggled to obtain the drugs necessary to administer lethal injections. Had the court barred the use of the drug at issue in Glossip, it could have made it difficult for states to carry out the death penalty at all.

The question put forward in Glossip is gruesome: Does the Constitution prohibit a state from using a lethal drug cocktail that could cause a prisoner excruciating pain during execution? The case was brought by a handful of death row inmates awaiting execution in Oklahoma—a state that gained notoriety for the botched execution of Clayton Lockett—who argue that the state cannot promise they will not feel intense pain during their impending executions.

The lethal injection protocol at issue in this case is a standard three-drug process. The first drug renders the prisoner unconscious so he or she feels no pain. The second causes paralysis so the prisoner cannot breathe. The third stops the prisoner’s heart.

But what if the first drug doesn’t work? The problem for Oklahoma and other states that administer the death penalty is that neither of the two drugs previously used to knock out the prisoner are currently available. So Oklahoma and two other states now use a third drug, midazolam, for this purpose. But midazolam is a sedative used to treat anxiety, not an anesthetic. The Oklahoma prisoners argued that it does not reliably render people unconscious; it didn’t work well for Lockett. They feared they would still feel the excruciating pain caused by the second and third drugs. The inmates were supported in an amicus brief by 16 pharmacology professors who argued midazolam is “incapable of inducing unconsciousness.” Justice Elena Kagan described the sensation of experiencing the latter drugs as the equivalent of “burning somebody alive” with a drug.

In trying to counter these arguments, Oklahoma relied on a single expert, an Auburn University pharmacist who has never used midazolam on a patient and whose expert-witness report included 150 pages printed off Drugs.com to support his claim that midazolam is sufficient to prevent pain in executions.

Nonetheless, today’s opinion is the second time the Supreme Court has upheld the constitutionality of lethal injection since 2008. As in the previous case from Kentucky, Baze v. Rees, the decision came down along ideological lines, which were evident during oral arguments—the most bitter of the term. The conservative justices appeared frustrated with what they saw as a backdoor attack on the death penalty itself. “This Court has held that the death penalty is constitutional,” Alito said during oral arguments in April. “Is it appropriate for the judiciary to countenance what amounts to a guerilla war against the death penalty which consists of efforts to make it impossible for the States to obtain drugs that could be used to carry out capital punishment with little, if any, pain? And so the States are reduced to using drugs like this one which give rise to disputes about whether, in fact, every possibility of pain is eliminated.”

On Monday, the answer was no.

WE'LL BE BLUNT.

We have a considerable $390,000 gap in our online fundraising budget that we have to close by June 30. There is no wiggle room, we've already cut everything we can, and we urgently need more readers to pitch in—especially from this specific blurb you're reading right now.

We'll also be quite transparent and level-headed with you about this.

In "News Never Pays," our fearless CEO, Monika Bauerlein, connects the dots on several concerning media trends that, taken together, expose the fallacy behind the tragic state of journalism right now: That the marketplace will take care of providing the free and independent press citizens in a democracy need, and the Next New Thing to invest millions in will fix the problem. Bottom line: Journalism that serves the people needs the support of the people. That's the Next New Thing.

And it's what MoJo and our community of readers have been doing for 47 years now.

But staying afloat is harder than ever.

In "This Is Not a Crisis. It's The New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, why this moment is particularly urgent, and how we can best communicate that without screaming OMG PLEASE HELP over and over. We also touch on our history and how our nonprofit model makes Mother Jones different than most of the news out there: Letting us go deep, focus on underreported beats, and bring unique perspectives to the day's news.

You're here for reporting like that, not fundraising, but one cannot exist without the other, and it's vitally important that we hit our intimidating $390,000 number in online donations by June 30.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. It's going to be a nail-biter, and we really need to see donations from this specific ask coming in strong if we're going to get there.

payment methods

WE'LL BE BLUNT.

We have a considerable $390,000 gap in our online fundraising budget that we have to close by June 30. There is no wiggle room, we've already cut everything we can, and we urgently need more readers to pitch in—especially from this specific blurb you're reading right now.

We'll also be quite transparent and level-headed with you about this.

In "News Never Pays," our fearless CEO, Monika Bauerlein, connects the dots on several concerning media trends that, taken together, expose the fallacy behind the tragic state of journalism right now: That the marketplace will take care of providing the free and independent press citizens in a democracy need, and the Next New Thing to invest millions in will fix the problem. Bottom line: Journalism that serves the people needs the support of the people. That's the Next New Thing.

And it's what MoJo and our community of readers have been doing for 47 years now.

But staying afloat is harder than ever.

In "This Is Not a Crisis. It's The New Normal," we explain, as matter-of-factly as we can, what exactly our finances look like, why this moment is particularly urgent, and how we can best communicate that without screaming OMG PLEASE HELP over and over. We also touch on our history and how our nonprofit model makes Mother Jones different than most of the news out there: Letting us go deep, focus on underreported beats, and bring unique perspectives to the day's news.

You're here for reporting like that, not fundraising, but one cannot exist without the other, and it's vitally important that we hit our intimidating $390,000 number in online donations by June 30.

And we hope you might consider pitching in before moving on to whatever it is you're about to do next. It's going to be a nail-biter, and we really need to see donations from this specific ask coming in strong if we're going to get there.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate